Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antitubercular Agents | 10 | 2020 | 35 | 2.270 |
Why?
|
| Anti-Bacterial Agents | 7 | 2023 | 432 | 1.860 |
Why?
|
| Carbolines | 4 | 2018 | 17 | 1.470 |
Why?
|
| Urea | 4 | 2023 | 46 | 1.240 |
Why?
|
| Peptides, Cyclic | 2 | 2020 | 29 | 1.180 |
Why?
|
| Structure-Activity Relationship | 15 | 2023 | 506 | 1.120 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 1019 | 1.060 |
Why?
|
| Indoles | 4 | 2018 | 187 | 1.010 |
Why?
|
| Macrocyclic Compounds | 3 | 2016 | 12 | 0.920 |
Why?
|
| Mycobacterium tuberculosis | 11 | 2020 | 109 | 0.880 |
Why?
|
| Biological Products | 2 | 2016 | 91 | 0.810 |
Why?
|
| Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) | 1 | 2023 | 1 | 0.810 |
Why?
|
| Bacteria | 3 | 2016 | 293 | 0.790 |
Why?
|
| Aromatase | 3 | 2018 | 20 | 0.780 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 3 | 2018 | 18 | 0.770 |
Why?
|
| Pharmacy | 1 | 2023 | 34 | 0.740 |
Why?
|
| Education, Pharmacy | 1 | 2023 | 57 | 0.730 |
Why?
|
| Molecular Structure | 10 | 2020 | 570 | 0.710 |
Why?
|
| Aromatase Inhibitors | 2 | 2018 | 19 | 0.680 |
Why?
|
| Heptanes | 1 | 2016 | 1 | 0.500 |
Why?
|
| Oxazines | 1 | 2016 | 32 | 0.500 |
Why?
|
| Carbazoles | 1 | 2016 | 49 | 0.460 |
Why?
|
| Inhibitory Concentration 50 | 4 | 2018 | 99 | 0.460 |
Why?
|
| Antimalarials | 1 | 2016 | 64 | 0.450 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 75 | 0.450 |
Why?
|
| NF-kappa B | 4 | 2014 | 358 | 0.430 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2014 | 8 | 0.420 |
Why?
|
| Antiviral Agents | 1 | 2016 | 195 | 0.410 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2020 | 245 | 0.410 |
Why?
|
| Enzyme Inhibitors | 3 | 2011 | 458 | 0.400 |
Why?
|
| Diarylheptanoids | 1 | 2013 | 2 | 0.400 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 134 | 0.390 |
Why?
|
| Nitric Oxide Synthase | 1 | 2012 | 135 | 0.370 |
Why?
|
| Stilbenes | 1 | 2012 | 44 | 0.360 |
Why?
|
| Pharmaceutical Preparations | 1 | 2013 | 94 | 0.360 |
Why?
|
| Flavonoids | 1 | 2012 | 100 | 0.350 |
Why?
|
| Peptide Library | 2 | 2007 | 28 | 0.330 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 187 | 0.330 |
Why?
|
| Ribonucleotide Reductases | 1 | 2009 | 7 | 0.310 |
Why?
|
| Deoxyadenosines | 1 | 2009 | 8 | 0.310 |
Why?
|
| Piperidines | 1 | 2009 | 83 | 0.290 |
Why?
|
| Adenosine Triphosphate | 1 | 2009 | 206 | 0.290 |
Why?
|
| Small Molecule Libraries | 4 | 2013 | 62 | 0.280 |
Why?
|
| Uridine | 1 | 2007 | 7 | 0.270 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2007 | 13 | 0.260 |
Why?
|
| Thymine | 1 | 2007 | 25 | 0.260 |
Why?
|
| Dipeptides | 1 | 2007 | 31 | 0.260 |
Why?
|
| Cyclization | 2 | 2020 | 50 | 0.260 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2018 | 97 | 0.250 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2018 | 128 | 0.240 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2020 | 301 | 0.220 |
Why?
|
| Amines | 2 | 2016 | 41 | 0.220 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 2676 | 0.220 |
Why?
|
| Neoplasms | 1 | 2016 | 1377 | 0.220 |
Why?
|
| Bacterial Infections | 2 | 2016 | 45 | 0.210 |
Why?
|
| Humans | 14 | 2023 | 43102 | 0.210 |
Why?
|
| Academies and Institutes | 1 | 2023 | 39 | 0.190 |
Why?
|
| Drug Design | 3 | 2014 | 186 | 0.180 |
Why?
|
| Escherichia coli | 2 | 2016 | 460 | 0.180 |
Why?
|
| Models, Molecular | 2 | 2016 | 876 | 0.180 |
Why?
|
| Educational Status | 1 | 2023 | 339 | 0.170 |
Why?
|
| Animals | 10 | 2018 | 16992 | 0.170 |
Why?
|
| Curriculum | 1 | 2023 | 318 | 0.160 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1723 | 0.160 |
Why?
|
| Catalytic Domain | 2 | 2017 | 118 | 0.150 |
Why?
|
| Cell Proliferation | 3 | 2015 | 1455 | 0.140 |
Why?
|
| Chemoprevention | 1 | 2018 | 41 | 0.140 |
Why?
|
| Biological Availability | 1 | 2018 | 116 | 0.140 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2016 | 9 | 0.130 |
Why?
|
| Bacillus subtilis | 1 | 2016 | 15 | 0.130 |
Why?
|
| Halogenation | 1 | 2016 | 19 | 0.130 |
Why?
|
| Gram-Positive Bacteria | 1 | 2016 | 21 | 0.120 |
Why?
|
| Cell Line | 4 | 2012 | 1410 | 0.120 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 45 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 1124 | 0.120 |
Why?
|
| Binding Sites | 1 | 2017 | 671 | 0.120 |
Why?
|
| Vero Cells | 3 | 2012 | 112 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2016 | 91 | 0.120 |
Why?
|
| Amides | 2 | 2014 | 71 | 0.120 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2016 | 110 | 0.110 |
Why?
|
| Mice | 6 | 2018 | 6644 | 0.110 |
Why?
|
| Malaria | 1 | 2016 | 90 | 0.110 |
Why?
|
| Fungi | 1 | 2016 | 106 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 157 | 0.110 |
Why?
|
| Spectinomycin | 1 | 2014 | 2 | 0.110 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2014 | 6 | 0.110 |
Why?
|
| Streptomyces | 1 | 2014 | 22 | 0.100 |
Why?
|
| Purine Nucleosides | 1 | 2014 | 14 | 0.100 |
Why?
|
| Hydrogenation | 1 | 2013 | 1 | 0.100 |
Why?
|
| Amination | 1 | 2013 | 6 | 0.100 |
Why?
|
| Chromatography | 1 | 2013 | 17 | 0.100 |
Why?
|
| Oximes | 1 | 2013 | 7 | 0.100 |
Why?
|
| Isomerism | 1 | 2013 | 64 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2014 | 384 | 0.100 |
Why?
|
| Leishmaniasis | 1 | 2012 | 8 | 0.100 |
Why?
|
| Leishmania donovani | 1 | 2012 | 18 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 127 | 0.100 |
Why?
|
| Trypanocidal Agents | 1 | 2012 | 40 | 0.090 |
Why?
|
| Nitric Oxide | 2 | 2013 | 386 | 0.090 |
Why?
|
| Cell Survival | 2 | 2012 | 945 | 0.090 |
Why?
|
| Receptors, Eph Family | 1 | 2011 | 4 | 0.090 |
Why?
|
| Epoxide Hydrolases | 1 | 2011 | 8 | 0.090 |
Why?
|
| Stereoisomerism | 2 | 2011 | 169 | 0.080 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2011 | 140 | 0.080 |
Why?
|
| Carbohydrate Epimerases | 1 | 2009 | 1 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2009 | 43 | 0.080 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2009 | 10 | 0.080 |
Why?
|
| Crystallography, X-Ray | 1 | 2009 | 280 | 0.070 |
Why?
|
| Oxazoles | 1 | 2008 | 19 | 0.070 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2009 | 199 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2009 | 108 | 0.070 |
Why?
|
| Isoxazoles | 1 | 2007 | 15 | 0.070 |
Why?
|
| Silanes | 1 | 2007 | 5 | 0.070 |
Why?
|
| Polystyrenes | 1 | 2007 | 20 | 0.070 |
Why?
|
| Apoptosis | 1 | 2015 | 1568 | 0.060 |
Why?
|
| Bacterial Proteins | 2 | 2014 | 595 | 0.030 |
Why?
|
| Arabinonucleosides | 1 | 2014 | 2 | 0.030 |
Why?
|
| Octamer Transcription Factor-2 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Ribosomes | 1 | 2014 | 35 | 0.030 |
Why?
|
| I-kappa B Proteins | 1 | 2013 | 36 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2014 | 36 | 0.030 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2014 | 84 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2013 | 84 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 105 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 82 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 108 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 137 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 239 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 299 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 883 | 0.020 |
Why?
|
| Female | 1 | 2011 | 24698 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 986 | 0.020 |
Why?
|
| Carbohydrate Dehydrogenases | 1 | 2009 | 12 | 0.020 |
Why?
|
| Tenuazonic Acid | 1 | 2009 | 1 | 0.020 |
Why?
|
| Pyrrolidinones | 1 | 2009 | 11 | 0.020 |
Why?
|
| Macrophages | 1 | 2013 | 529 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2009 | 74 | 0.020 |
Why?
|
| Aorta | 1 | 2009 | 198 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2009 | 204 | 0.020 |
Why?
|
| Nitrofurans | 1 | 2007 | 3 | 0.020 |
Why?
|
| Furans | 1 | 2008 | 40 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2009 | 281 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2013 | 518 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2009 | 408 | 0.020 |
Why?
|
| Biofilms | 1 | 2009 | 184 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2009 | 329 | 0.020 |
Why?
|
| Rats | 1 | 2007 | 3735 | 0.010 |
Why?
|
| Male | 1 | 2009 | 23409 | 0.000 |
Why?
|